Executives of Depomed announced that they have achieved significant milestones in the third and early fourth quarter and have also completed a transaction with Merck that has provided them a reason to rejoice and have a stronger and profitable balance sheet this quarter. Depomed is a specialty pharmaceutical company which has many product candidates in the pipeline with few of products already in Phase 3 trials.http://www.favstocks.com/depomed-q3-fina...’s GLUMETZA (metformin hydrochloride extended release tablets) has already been approved for use in adults with Type 2 diabetes and the prescriptions for GLUMETZA have reached all time high and additionally they have received positive results with their Phase 3 postherpetic neuralgia study with DM-1796.